TY - CHAP M1 - Book, Section TI - Bladder Cancer A1 - Siefker-Radtke, Arlene O. A1 - Czerniak, Bogdan A. A1 - Dinney, Colin P.N. A1 - McConkey, Commentary: David J. A2 - Kantarjian, Hagop M. A2 - Wolff, Robert A. PY - 2016 T2 - The MD Anderson Manual of Medical Oncology, 3e AB - Expectant optimism is now pervading the field of urothelial cancer as we anticipate that we will soon be soaring above the plateaus established with cisplatin-based chemotherapy in the 1980s and finally have new agents approved for the treatment of urothelial carcinoma. Immune checkpoint inhibitors, which are transforming the field of oncology, are showing evidence of clinical activity in early clinical trials in this disease (1). In addition, there are several ongoing trials of targeted agents including fibroblast growth factor (FGF) receptor inhibitors and vascular endothelial growth factor (VEGF) inhibitors currently in clinical trials with the goal of obtaining US Food and Drug Administration (FDA) approval. Our fundamental understanding of the biology of urothelial cancer is changing as well, with molecular characterization suggesting that urothelial cancer is no longer only one disease (2). These nascent technologies suggest we will soon be able to personalize therapy for urothelial cancer and reliably predict which patients will benefit from specific chemotherapy and/or other targeted agents, transforming our current treatment of urothelial cancer. SN - PB - McGraw-Hill Medical CY - New York, NY Y2 - 2024/03/28 UR - hemonc.mhmedical.com/content.aspx?aid=1126744441 ER -